Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug monotherapy of cancer

International Journal of Molecular Sciences

Volumn 9, Issue 5, 2008, Pages 821-837

  Tietze, Lutz F ^a   Panknin, Olaf ^a   Krewer, Birgit ^a   Major, Felix ^a   Schuberth, Ingrid ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antibiotics; Antitumor agents; Pentagastrin; Prodrug; Prodrug monotherapy

Indexed keywords

1 CHLOROMETHYL 5 (PHENYLALANINAMIDYLASPARTYLMETHIONYLTRYPTOPHYL BETA ALANYL CARBONYLOXY) 3 (5,6,7 TRIMETHOXYINDOLE 2 CARBONYL) 2,3 DIHYDRO 1H BENZ[E]INDOLE 7 CARBOXYLIC ACID [2 (TRIMETHYLSILYL)ETHER]ESTER; 1 CHLOROMETHYL 5 HYDROXY 3 (5,6,7 TRIMETHOXYINDOLE 2 CARBONYL) 2,3 DIHYDRO 1H BENZ[E]INDOLE 7 CARBOXYLIC ACID [2 (TRIMETHYLSILYL)ETHYL]ESTER; 5 BENZYLOXY 3 (TERT BUTOXYCARBONYL) 1 CHLOROMETHYL 2,3 DIHYDRO 1H BENZ[E]INDOLE 7 CARBOXYLIC ACID [2 (TRIMETHYLSILYL)ETHYL]ESTER; ANTINEOPLASTIC AGENT; BROMIDE; CARBAMIC ACID DERIVATIVE; CHOLECYSTOKININ RECEPTOR; DUOCARMYCIN SA; PALLADIUM; PENTAGASTRIN; PIBROZELESIN; PRODRUG; TOXIN;

ARTICLE; BIOTRANSFORMATION; CARBONYLATION; CATALYSIS; CONJUGATE; CONTROLLED STUDY; CYCLIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG SCREENING; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; PHARMACOPHORE;

EID: 44649117438     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9050821     Document Type: Article

References (76)

1. a) Bagshawe, K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 1987, 56, 531-532;
2. Reviews: b) Tietze, L.F.; Feuerstein T. Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy. Curr. Pharm. Des. 2003, 9, 2155-2175;
3. c) Tietze, L.F.; Feuerstein, T. Highly Selective Compounds for the Antibody-Directed Enzyme Prodrug Therapy of Cancer. Aust. J. Chem. 2003, 56, 841-854;
4. d) Jung, M. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Mini-Rev. Med. Chem. 2001, 1, 399-407;
5. e) Syrigos, K.N.; Epenetos, A.A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. 1999, 19, 605-613;
6. f) Springer, C.J.; Niculescu-Duvaz, I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Deliv. Rev. 1997, 26, 151-172.
7. a) Tietze, L.F.; Major, F.; Schuberth, I.; Spiegl, D.A.; Krewer, B.; Maksimenka, K.; Bringmann, G.; Magull, J. Selective Treatment of Cancer: Synthesis, Biological Evaluation and Structural Elucidation of Novel Analogues of the Antibiotic CC-1065 and the Duocarmycins. Chem. Eur. J. 2007, 13, 4396-4409;
8. b) Tietze, L.F.; Major, F.; Schuberth, I.. Antitumor Agents: Development of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy. Angew. Chem. 2006, 118, 6724-6727;
9. Angew. Chem., Int. Ed. 2006, 45, 6574-6577;
10. c) Tietze, L.F.; Krewer, B.; Frauendorf, H.; Major, F.; Schuberth, I. Investigation of Reactivity and Selectivity of DNA-Alkylating Duocarmycin Analogues by High-Resolution Mass Spectrometry. Angew. Chem. 2006, 118, 6720-6724;
11. Angew. Chem., Int. Ed. 2006, 45, 6570-6574.
12. a) Ganesh, T. Improved biochemical strategies for targeted delivery of taxoids. Bioorg. Med. Chem. 2007, 15, 3597-3623;
13. b) Devalapally, H.; Navath, R.S.; Yenamandra, V.; Akkinepally, R.R.; Devarakonda, R.K. Directed Enzyme Prodrug Therapy/Prodrug MonoTherapy. Arch. Pharm. Res. 2007, 30, 723-732;
14. c) Alaoui, A.E.; Saha, N.; Schmidt, F.; Monneret, C.; Florent, J.-C. New Taxol®(paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. 2006, 14, 5012-5019;
15. d) Kratz, F.; Warnecke, A.; Schmid, B.; Chung, D.-E.; Gitzel, M. Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. 2006, 13, 477-523;
16. e) Schmidt, F.; Monneret, C. Prodrug Monotherapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg. Med. Chem. 2003, 11, 2277-2283;
17. f) Prijovich, Z.M.; Chen, B.M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S.R. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9 ACG) in mice. Br. J. Cancer 2002, 86, 1634-1638;
18. g) Denny, W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 2001, 36, 577-595;
19. h) Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H.K.; Gesson, J.-P.; Koch, M.; Monneret, C. Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy. Cancer Res. 1998, 58, 1195-1201;
20. i) Bosslet, K.; Czech, J.; Hoffmann, D. Tumor Targeting 1995, 1, 45-50.
21. Reviews: a) Reubi, J.C.; Mäcke, H.R.; Krenning, E.P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med. 2005, 46, 67S-75S;
22. b) Dyba, M.; Tarasova, N.I.; Michejda, C.J. Small Molecule Toxins Targeting Tumor Receptors. Curr. Pharm. Des. 2004, 10, 2311-2334;
23. c) Reubi, J.C. Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy. Endocrine Reviews 2003, 24, 389-427;
24. d) Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. 2003, 30, 781-793;
25. e) Langer, M.; Beck-Sickinger, A.G. Peptides as Carrier for Tumor Diagnosis and Treatment. Curr. Med. Chem. 2001, 1, 71-93;
26. f) Breeman, W.A.P.; de Jong, M.; Kwekkeboom, D.J.; Valkema, R.; Bakker, W.H.; Kooij, P.P.M.; Visser, T.J.; Krenning, E.P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 2001, 28, 1421-1429;
27. g) Heppeler, A.; Froidevaux, S.; Eberle, A.N.; Maecke, H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 2000, 7, 971-994.
28. 99mTc-Labeled Minigastrin Analogs. J. Nucl. Med. 2005, 46, 1727-1736;
29. b) Béhé, M.; Behr, T. M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers (Peptide Science) 2002, 66, 399-418;
30. c) Behr, T.M.; Jenner, N.; Béhé, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled Peptides for Targeting Cholecystokinin-B/Gastrin Receptor-Expressing Tumors. J. Nucl. Med. 1999, 40, 1029-1044;
31. d) Behr, T.M.; Jenner, N.; Radetzky, S.; Béhé, M.; Gratz, S.; Yücekent, S.; Raue, F.; Becker, W. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur. J. Nucl. Med. 1998, 25, 424-430.
32. Schmidt, B.F.; Hernandez, L.; Rouzer, C.; Czerwinski, G.; Chmurny, G.; Michejda, C.J. Peptide-Linked 1,3-Dialkyl-3-acyltriazenes:Gastrin Receptor Directed Antineoplastic Alkylating Agents. J. Med. Chem. 1994, 37, 3812-3818.
33. Czerwinski, G.; Tarasova, N.I.; Michejda, C.J. Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug. Proc. Natl. Acad. Sci. USA 1998, 95, 11520-11525.
34. a) Buchholz, S.; Keller, G.; Schally, A.V.; Halmos, G.; Hohla, F.; Heinrich, E.; Koester, F.; Baker, B.; Engel, J.B. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc. Natl. Acad. Sci. USA, 2006, 103, 10403-10407;
35. b) Nagy, A.; Schally, A.V. Minireview. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers. Biol. Reprod. 2005, 73, 851-859;
36. c) Nagy, A.; Schally, A.V.; Armatis, P.; Szepesházi, K.; Halmos, G.; Kovács, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwirth, A.; Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. USA, 1996, 93, 7269-7273.
37. a) Engel, J.B.; Keller, G.; Schally, A.V.; Halmos, G.; Hammann, B.; Nagy, A. Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215. Clin. Cancer Res. 2005, 11, 2408-2415;
38. b) Nagy, A.; Armatis, P.; Cai, R.Z.; Szepesházi, K.; Halmos, G.; Schally, A.V. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA, 1997, 94, 652-656.
39. a) Szepesházi, K.; Schally, A.V.; Halmos, G.; Armatis, P.; Hebert, F.; Sun, B.; Feil, A.; Kiaris, H.; Nagy, A. Targeted Cytotoxic Somatostatin Analogue AN-238 Inhibits Somatostatin Receptor-positive Experimental Colon Cancers Independently of Their p53 Status. Cancer Res. 2002, 62, 781-788;
40. b) Nagy, A.; Schally, A.V.; Halmos, G.; Armatis, P.; Cai, R.Z.; Csernus, V.; Kovács, M.; Koppán, M.; Szepesházi, K.; Kahán, Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2- pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA, 1998, 95, 1794-1799.
41. Langer, M.; Kratz, F.; Rothen-Rutishauser, B.; Wunderli-Allenspach, H.; Beck-Sickinger, A.G. Novel Peptide Conjugates for Tumor-Specific Chemotherapy. J. Med. Chem. 2001, 44, 1341-1348.
42. Tietze, L.F.; Panknin, O.; Major, F.; Krewer, B. Synthesis of a Novel Pentagastrin-Drug Conjugate for a Targeted Tumor Therapy. Chem. Eur. J. 2008, 14, 2811-2818.
43. a) Boger, D.L.; Johnson, D.S. CC-1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies. Angew. Chem. 1996, 108, 1542-1580;
44. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438-1474;
45. b) Ichimura, M.; Ogawa, T.; Katsumata, S.; Takahashi, K.; Takahashi, I.; Nakano, H. Duocarmycins, new antitumor antibiotics produced by streptomyces; producing organisms and improved production. J. Antibiot. 1991, 44, 1045-1053;
46. c) Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin, a new antitumor antibiotic from streptomyces sp. J. Antibiot. 1990, 43, 1037-1038.
47. a) Boger, D.L.; Bollinger, B.; Hertzog, D.L.; Johnson, D.S.; Cai, H.; Mésini, P.; Garbaccio, R.M.; Jin, Q.; Kitos, P.A. Reversed and Sandwiched Analogs of Duocarmycin SA: Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis. J. Am. Chem. Soc. 1997, 119, 4987-4998;
48. b) Boger, D.L.; Johnson, D.S. CC-1065 and the Duocarmycins: Understanding their Biological Function through Mechanistic Studies. Angew. Chem. 1996, 108, 1542-1580;
49. Angew. Chem. Int. Ed. Engl. 1996, 35, 1438-1474;
50. c) Hurley, L.H.; Needham-VanDevanter, D.R. Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo( 1,4) benzodiazepines. Acc. Chem. Res. 1986, 19, 230-237.
51. a) Tietze, L.F.; Haunert, F.; Feuerstein, T.; Herzig, T. A Concise and Efficient Synthesis of seco-Duocarmycin SA. Eur. J. Org. Chem. 2003, 3, 562-566;
52. [UNK]-3 Participation. Isolation and Behavior of Spiro(2,5)octa-1,4-diene-3-one. J. Am. Chem. Soc. 1963, 85, 567-578.
53. a) Morley, J.S.; Tracy, H.J.; Gregory, R.A. Structure-Function Relationships in the Active C-Terminal Tetrapeptide Sequence of Gastrin. Nature 1965, 207, 1356-1359;
54. b) Tracy, H.J.; Gregory, R.A. The antral Hormone Gastrin: Physiological Properties of a Series of Synthetic Peptides structurally related to Gastrin I. Nature 1964, 204, 935-938.
55. a) Alberts, S.R.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Richardson, R.L.; Goldberg, R.M. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res. 1998, 4, 2111-2117;
56. b) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on the active metabolite (DU-86) of KW-2189, a novel derivative of duocarmycin. Bioorg. Med. Chem. Lett. 1996, 6, 2147-2150;
57. c) Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole analogues of duocarmycin B2. Bioorg. Med. Chem. 1996, 4, 1379-1391;
58. d) Nagamura, S.; Asai, A.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives: Modification of Segment A of Duocarmycin B2. Chem. Pharm. Bull. 1996, 44, 1723-1730;
59. e) Yasuzawa, T.; Muroi, K.; Ichimura, M.; Takahashi, I.; Ogawa, T.; Takahashi, K.; Sano, H.; Saitoh, Y. Duocarmycins, Potent Antitumor Antibiotics Produced by Streptomyces sp. Structures and Chemistry. Chem. Pharm. Bull. 1995, 43, 378-391;
60. f) Asai, A.; Nagamura, S.; Saito, S. A Novel Property of Duocarmycin and Its Analogs for Covalent Reaction with DNA. J. Am. Chem. Soc. 1994, 116, 4171-4177.
61. Ray, S.; Chaturvedi, D. Application of organic carbamates in drug design. Part 1: Anti-cancer agents-recent reports. Drugs Fut. 2004, 29, 343-357.
62. Kaiser, N.-F.; Hallberg, A.; Larhed, M. In situ Generation of Carbon Monoxide from Solid Molybdenum Hexacarbonyl. A Convenient and Fast Route to Palladium-Catalyzed Carbonylation Reactions. J. Comb. Chem. 2002, 4, 109-111.
63. Boger, D.L.; Han, N.; Tarby, C.M.; Boyce, C.W.; Cai, H.; Jin, Q.; Kitos, P.A. Synthesis, Chemical Properties, and Preliminary Evaluation of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one Alkylation Subunit: Hammett Quantitation of the Magnitude of Electronic Effects on Functional Reactivity. J. Org. Chem. 1996, 61, 4894-4912.
64. a) Boger, D.L.; Brunette, S.R.; Garbaccio, R.M. Synthesis and Evaluation of a Series of C3-Substituted CBI Analogues of CC-1065 and the Duocarmycins. J. Org. Chem. 2001, 66, 5163-5173;
65. b) Boger, D.L.; McKie, J.A.; Cai, H.; Cacciari, B.; Baraldi, P.G. Synthesis and Properties of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Methoxy-1,2,9,9a-tetrahydrocyclopropa[c] benz[e]indol-4-one (MCBI) Alkylation Subunit: Magnitude of Electronic Effects on the Functional Reactivity. J. Org. Chem. 1996, 61, 1710-1729.
66. a) Boger, D.L.; Boyce, C.W.; Garbaccio, R.M.; Searcey, M. Synthesis of CC-1065 and duocarmycin analogs via intramolecular aryl radical cyclization of a tethered vinyl chloride. Tetrahedron Lett. 1998, 39, 2227-2230;
67. b) Patel, V.F.; Andis, S.L.; Enkema, J.K.; Johnson, D.A.; Kennedy, J.H.; Mohamadi, F.; Schultz, R.M.; Soose, D.J.; Spees, M.M. Total Synthesis of Seco (+)- and ent-(-)-Oxaduocarmycin SA: Construction of the (Chloromethyl)indoline Alkylating Subunit by a Novel Intramolecular Aryl Radical Cyclization onto a Vinyl Chloride. J. Org. Chem. 1997, 62, 8868-8874;
68. c) Boger, D.L.; McKie, J.A. An Efficient Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one CBI: An Enhanced and Simplified Analog of the CC-1065 and Duocarmycin Alkylation Subunits. J. Org. Chem. 1995, 60, 1271-1275.
69. a) Studer, A.; Amrein, S. Silylated Cyclohexadienes: New Alternatives to Tributyltin Hydride in Free Radical Chemistry. Angew. Chem. 2000, 112, 3196-3198;
70. Angew. Chem. Int. Ed. 2000, 39, 3080-3082;
71. b) Chatgilialoglu, C. Organosilanes as radical-based reducing agents in synthesis. Acc. Chem. Res. 1992, 25, 188.
72. Belshaw, P.J.; Mzengeza, S.; Lajoie, G.A. Chlorotrimethylsilane Mediated Formation of ω-Allyl Esters of Aspartic And Glutamic Acids. Synth. Commun. 1990, 20, 3157-3160.
73. Mehta, A.; Jaouhari, R.; Benson, T.J.; Douglas, K.T. Improved efficiency and selectivity in peptide synthesis: use of triethylsilane as a carbocation scavenger in deprotection of t-butyl esters and t-butoxycarbonyl-protected sites. Tetrahedron Lett. 1992, 33, 5441-5444.
74. a) Ram, S.; Spicer, L.D. Rapid debenzylation of N-benzylamino derivatives to amino-derivatives using ammonium formate as catalytic hydrogen transfer agent. Tetrahedron Lett. 1987, 28, 515-516;
75. b) Bieg, T.; Szeja, W. Removal of-Benzyl Protective Groups by Catalytic Transfer Hydrogenation. Synthesis 1985, 76-77.
76. Tetragastrin (20) was purchased from Bachem.